Home / Health / Alzheimer's Treatment: New Hope Beyond Plaques
Alzheimer's Treatment: New Hope Beyond Plaques
31 Mar
Summary
- New compound FLAV-27 targets gene expression, not just plaques.
- It inhibits the G9a enzyme to reprogram neuronal epigenetics.
- FLAV-27 shows promise in cell, nematode, and mouse models.
Researchers have developed a novel compound, FLAV-27, that offers a new strategy for treating Alzheimer's disease. Unlike existing drugs that target amyloid-beta plaques, FLAV-27 focuses on reprogramming the epigenome of neurons.
This innovative approach targets upstream changes in gene expression that contribute to the disease's progression. FLAV-27 inhibits an enzyme called G9a, which is involved in epigenetic regulation and can silence genes crucial for brain function.
While still in early stages, FLAV-27 has demonstrated promising results in laboratory settings. It has shown potential in reducing amyloid-beta plaques and tau tangles in mouse brain cells.
In further studies, the compound improved mobility and lifespan in nematode worms and restored memory and social behavior in mouse models of Alzheimer's. These findings suggest epigenetic dysregulation may be a central mechanism in the disease.
FLAV-27 has not yet been tested in humans and faces rigorous toxicology studies and regulatory steps before human trials can begin. The study was published in Molecular Therapy.
